Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei Ping Lu, Anu Gupta, Cynthia B. Leary, Scott C. Wise, Thomas J. Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L. Bulfer, Timothy M. Caldwell, Lawrence Chun, Carol L. Ensinger, Molly M. Hood, Arin McKinley, William C. Patt, Rodrigo Ruiz-Soto, Ying Su, Hanumaiah Telikepalli, Ajia TownBenjamin A. Turner, Lakshminarayana Vogeti, Subha Vogeti, Karen Yates, Filip Janku, Albiruni Ryan Abdul Razak, Oliver Rosen, Michael C. Heinrich, Daniel L. Flynn

Research output: Contribution to journal › Article › peer-review

175 Scopus citations

Fingerprint

Dive into the research topics of 'Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants'. Together they form a unique fingerprint.

Medicine & Life Sciences